查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916509

全球兽药市场：市场规模、份额、成长率、产业分析、按类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Veterinary Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 210 Pages | 商品交期: 请询问到货日

价格

兽药市场成长驱动因素

预计2025年全球兽药市场规模将达到472.5亿美元，2026年将成长至496.5亿美元，到2034年将达到815.9亿美元。预计在预测期内（2026-2034年），其复合年增长率（CAGR）为6.40%。北美地区引领全球兽药市场，预计2025年将占40.02%的市场。这主要得益于北美地区较高的宠物拥有率、完善的动物照护基础设施以及先进的畜牧养殖技术。

兽药市场包括用于预防、治疗和改善伴侣动物和牲畜生产性能的药品、疫苗和含药饲料添加剂。该市场在控制人畜共患病、维护食品安全和改善动物福利方面发挥关键作用。

市场驱动因素

宠物饲养量和兽医保健支出的成长是主要驱动因素。预计到2024年，美国犬隻数量将达到5,980万隻，猫的数量将达到4,220万隻，平均每个家庭每年在犬隻和猫身上的支出分别为580美元和433美元，这将推动对预防性和慢性病药物的需求。

为满足不断增长的全球蛋白质需求而扩大畜牧业规模也促进了市场成长。根据世界动物卫生组织（OIE）统计，全球77.0%的牲畜受到口蹄疫的影响，这将推动对疫苗和早期疾病管理的需求。寄生虫感染、牛乳腺炎、犬小病毒和蜱传疾病病例的增加进一步推动了对治疗的需求。

新产品的推出持续推动成长。 2024年9月，Eleanco公司的Zenrelia获得FDA批准，这是一种用于治疗犬过敏性皮肤炎的每日一次口服药物，标誌着伴侣动物治疗领域的创新取得了进展。

市场限制因子

因副作用或安全问题导致的产品召回可能会削弱消费者信心。 2021年6月，英国一家兽药药局因安全问题召回了Seba公司的Salmovac 400疫苗。 2023年12月，澳洲在收到包括致命病例在内的严重副作用报告后，召回了犬隻用Tridoria Auslepto疫苗。此类事件可能导致品牌声誉受损和监管审查加剧，进而抑制市场成长。

市场机会

研发投入和监管审批正在创造成长机会。 2024年4月，FDA批准了Pradarex注射液用于治疗牛和猪的呼吸道疾病，从而扩大了畜牧业疾病管理的选择。对先进生物製剂和标靶疗法的日益重视，在提高安全性的同时，也为疾病管理提供了支持。

农民和宠物主人对预防保健意识的提高，也推动了疫苗接种计划和早期诊断的普及，从而扩大了新兴经济体的市场潜力。

市场挑战

抗菌素抗药性（AMR）是一个重大挑战，尤其是在抗生素滥用普遍存在的低收入农业地区。 2024年9月，世界动物卫生组织（OIE）估计，到2025年，抗菌素抗药性可能导致全球医疗保健成本增加1,890亿美元。更严格的抗生素监管限制了药物的供应，影响了畜牧业生产力，阻碍了治疗药物市场的成长。

市场趋势

基因疗法和细胞疗法正成为兽医学领域新兴的创新治疗方法。 2024年12月，Protect Animal Health与Rejuvenate Bio合作开发PT-401，一种用于治疗犬二尖瓣疾病的基因疗法。这标誌着动物医疗正朝着个人化方向发展。

此外，新冠疫情期间远距医疗的普及扩大了处方药的取得途径和慢性病监测的覆盖范围，进一步推动了治疗药物的销售。

依细分市场分析

依产品分类

预计到2026年，动物保健产品将占据市场主导地位，市占率高达64.87%，这主要得益于疾病的高发生率和仿製药的核准。 2024年6月，美国食品药物管理局（FDA）批准苯丙醇胺咀嚼片用于治疗犬尿失禁，进一步提振了药品销售。疫苗对于传染病控制至关重要，一种新的牛呼吸道疾病（BRD）疫苗正在研发中。用于提高牲畜生产力和饲料转换率的药用饲料添加剂市场稳定成长。

依动物类型划分

2025年，伴侣动物占了46.1%的市场份额，这得益于宠物饲养率的上升和预防性医疗支出的增加。由于蛋白质需求增加和疾病预防计画的实施，家畜在2026年成为主导动物，预计2025年至2032年的复合年增长率（CAGR）为5.42%。

依给药途径划分

2024年，在政府疫苗接种计画的支持下，肠外给药成为​​疫苗接种和紧急治疗的主要途径。预计到 2026 年，口服药物的市场份额将达到 47.23%，这主要得益于 Zenrelia 片剂等产品的推动。外用药物预计将因皮肤病的增加而增长，而气雾剂疗法预计将温和扩张。

依通路划分

由于宠物定期体检和门诊就诊的频率较高，预计从 2025 年到 2032 年，兽医诊所的复合年增长率将达到 6.14%，在分销管道中占据领先地位。在先进诊断协作的支持下，预计到 2026 年，兽医院的市占率将达到 40.99%。药局则透过改善药品取得途径和提供诊所内配药服务而成长。

区域展望

北美市场规模预计在2025年达到189.1亿美元，2026年达到201亿美元。美国预计将引领市场，到2026年市场规模将达到189.3亿美元。欧洲市场规模预计达到120.1亿美元，这得益于强而有力的政府福利计画和製造业产能。亚太地区预计在2026年将达到88亿美元，其中中国（15.3亿美元）、印度（15.7亿美元）和日本（33亿美元）将引领市场。拉丁美洲预计在2025年将达到50.2亿美元，而海湾合作委员会（GCC）市场在2025年将达到15亿美元，这得益于药物警戒改革和疾病控制计画。 《全球兽药市场》报告对全球兽药产业进行了全面分析，详细评估了2025年、2026年和2034年的市场规模和价值，并预测了2026年至2034年复合年增长率（CAGR）为6.40%的成长轨迹。本报告考察了兽药、兽用疫苗和药用饲料添加剂等关键产品类别，并评估了它们在伴侣动物和牲畜中的应用。此外，报告还按给药途径（口服、注射、外用、气雾剂）和分销管道（兽医院、动物诊所、药房等）分析了市场。

本报告深入评估了市场驱动因素、限制因素、机会、挑战和新兴趋势，重点分析了宠物饲养率上升、牲畜疾病负担加重、抗菌素抗药性以及基因和细胞疗法兴起等因素的影响。区域分析涵盖北美、欧洲、亚太、拉丁美洲以及中东和非洲，并针对美国、英国、德国、法国、中国、印度和日本等主要市场提供国别分析。报告采用经核实的2025年和2026年市场价值数据。本报告重点介绍主要企业，包括硕腾（Zoetis）、默克动物保健（Merck Animal Health）、礼来（Elanco）、勃林格殷格翰（Boehringer Ingelheim）、西瓦（Ceva）、维克（Virbac）和维托奎诺（Vetoquinol），并追踪影响其近期竞争地位的产品审查此外，报告还评估了新冠疫情、监管趋势、药物警戒系统和永续发展措施等因素对产业长期发展的影响。

依产品类型划分，兽药将在2026年占据64.87%的市场份额，这反映出市场对传染病、寄生虫病和慢性动物疾病治疗药物的高需求。同时，疫苗对于预防疫情爆发至关重要，而饲料添加剂则有助于提高商业农业的生产力。儘管伴侣动物在2025年占据了46.1%的市场份额，但由于全球蛋白质消费量的增长和生物安全措施的日益严格，畜牧业将在2026年占据主导地位。儘管抗菌素抗药性、产品召回和监管力度加大等挑战仍在影响着产品的使用模式，但强大的研发管线、靶向生物製剂获批数量的增加以及基因和细胞疗法的兴起正在重塑未来的治疗模式。总体而言，持续的创新、预防性药物的普及以及不断扩大的兽药治疗基础设施预计将确保兽药治疗在全球动物保健领域保持重要且不断增长的地位。

目录

第一章：引言

第二章：执行摘要

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区动物疾病概览（2025 年）
  • 在开发产品分析
  • 主要国家和地区监管状况（2025 年）
  • 价格分析
  • 主要国家和地区宠物拥有量统计（2025 年）
  • 新疗法与在研疗法概述
  • 各种疾病治疗方案概述动物疾病
  • 主要公司新产品发布
  • 主要产业趋势：併购、合作等
  • 新冠疫情对全球兽药市场的影响

第五章 全球兽药市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品分类
    • 兽药
      • 抗感染药
      • 抗发炎药
      • 驱虫药
      • 其他
    • 兽用疫苗
      • 灭活​​疫苗
      • 减毒活疫苗疫苗
      • 重组疫苗
      • 其他疫苗
    • 药用饲料添加剂
      • 抗菌剂
      • 抗球虫剂
      • 驱虫药
      • 其他药物
  • 市场分析、洞察与预测：依动物类型划分
    • 伴侣动物
      • 猫
      • 狗
      • 鸟类
      • 其他动物
    • 牲畜
      • 家禽
      • 猪
      • 牛
      • 其他动物
  • 市场分析、洞察与预测：依给药途径划分给药途径
    • 口服
    • 注射
    • 局部用药
    • 气雾剂
  • 市场分析、洞察与预测：依销售管道划分
    • 兽医院
    • 兽医诊所
    • 药局和药局
    • 其他
  • 市场分析、洞察与预测：按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美兽药市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲兽药市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家

第八章：亚太地区兽药市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲兽药市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲兽药市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家
    • 南非
    • 其他中东和非洲国家国家/地区

第11章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
    • Zoetis Services LLC
    • Merck Animal Health
    • Elanco
    • Boehringer Ingelheim International GmbH.
    • Ceva
    • Vetoquinol
    • Virbac
    • Phibro Animal Health Corporation
    • Panav Bio Tech.
Product Code: FBI100138

Growth Factors of veterinary therapeutics Market

The global veterinary therapeutics market size was valued at USD 47.25 billion in 2025 and is projected to grow to USD 49.65 billion in 2026, reaching USD 81.59 billion by 2034, registering a CAGR of 6.40% during the forecast period (2026-2034). North America dominated the global veterinary therapeutics market with a 40.02% market share in 2025, supported by high pet ownership rates, strong veterinary healthcare infrastructure, and advanced livestock farming practices.

Veterinary therapeutics includes drugs, vaccines, and medicated feed additives used for disease prevention, treatment, and productivity improvement in both companion and livestock animals. The market plays a critical role in controlling zoonotic diseases, maintaining food safety, and improving animal welfare.

Market Drivers

Rising pet ownership and increasing expenditure on animal health are primary drivers. In the U.S., pet ownership reached 59.8 million dogs and 42.2 million cats in 2024, with average annual household spending of USD 580 for dogs and USD 433 for cats, driving demand for preventive medicines and chronic disease treatments.

Growing livestock production to meet rising global protein demand also contributes to market expansion. According to the World Organization for Animal Health, 77.0% of global livestock is affected by foot-and-mouth disease, increasing demand for vaccines and early disease management. Rising cases of parasitic infections, bovine mastitis, canine parvovirus, and tick-borne diseases further elevate therapeutic demand.

Product launches continue to stimulate growth. In September 2024, Elanco received FDA approval for Zenrelia, a once-daily oral treatment for allergic dermatitis in dogs, reflecting increasing innovation in companion animal therapeutics.

Market Restraints

Product recalls due to adverse reactions and safety issues reduce consumer confidence. In June 2021, the U.K. Veterinary Medicines Directorate recalled Salmovac 400 vaccine produced by CEVA due to safety concerns. In December 2023, Australia recalled Triedlia Auslepto vaccine for dogs after reports of severe adverse reactions, including fatality. Such incidents impact brand reputation and regulatory scrutiny, restraining market growth.

Market Opportunities

R&D investment and regulatory approvals are generating growth opportunities. In April 2024, the FDA approved Pradalex injection for treating bovine and swine respiratory diseases, expanding livestock disease management options. Increased focus on advanced biologics and targeted therapies supports disease control with improved safety profiles.

Growing awareness among farmers and pet owners regarding preventive healthcare also increases adoption of vaccination programs and early diagnostics, expanding market potential across emerging economies.

Market Challenges

Antimicrobial resistance (AMR) presents a major challenge, particularly in low-income agricultural regions where antibiotic misuse is common. In September 2024, the World Organization for Animal Health estimated that antimicrobial resistance could increase global healthcare costs by USD 189.0 billion by 2025. Stricter antimicrobial regulations limit drug availability and affect livestock productivity, challenging therapeutic market growth.

Market Trends

Gene and cell therapies are emerging as innovative treatment approaches in veterinary medicine. In December 2024, Protect Animal Health partnered with Rejuvenate Bio to develop gene therapy PT-401 for treating mitral valve disease in dogs, indicating a shift toward personalized veterinary medicine.

Telemedicine adoption during COVID-19 also increased prescription access and monitoring of chronic conditions, further supporting therapeutic sales.

Segmentation Analysis

By Product

Veterinary drugs dominated with 64.87% share in 2026, driven by high disease prevalence and generic drug approvals. FDA approval of phenylpropanolamine chewable tablets in June 2024 for canine urinary incontinence further strengthened drug sales. Vaccines remain essential for infectious disease control, with new BRD vaccines under development. Medicated feed additives grow steadily to improve livestock productivity and feed efficiency.

By Animal Type

Companion animals accounted for 46.1% share in 2025, supported by rising pet ownership and preventive healthcare spending. Livestock dominated in 2026 due to increased protein demand and disease prevention programs, growing at 5.42% CAGR during 2025-2032.

By Route of Administration

Parenteral routes dominated in 2024 due to vaccine delivery and emergency treatments, supported by government vaccination programs. Oral therapeutics are expected to reach 47.23% share in 2026, driven by products such as Zenrelia tablets. Topical formulations grow due to rising dermatological conditions, while aerosol therapies expand moderately.

By Distribution Channel

Veterinary clinics dominated due to frequent pet checkups and outpatient services, growing at 6.14% CAGR during 2025-2032. Veterinary hospitals are expected to reach 40.99% share in 2026, supported by advanced diagnostic collaborations. Pharmacies grow through improved accessibility and in-clinic dispensing services.

Regional Outlook

North America generated USD 18.91 billion in 2025 and USD 20.10 billion in 2026, led by the U.S. reaching USD 18.93 billion in 2026. Europe reached USD 12.01 billion with strong government welfare programs and manufacturing capabilities. Asia Pacific is projected at USD 8.80 billion in 2026, driven by China (USD 1.53 billion), India (USD 1.57 billion), and Japan (USD 3.30 billion). Latin America reached USD 5.02 billion in 2025, while GCC markets reached USD 1.50 billion in 2025, supported by pharmacovigilance reforms and disease control programs.

Competitive Landscape

Major players including Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim, Ceva, Vetoquinol, and Virbac lead through product approvals and global expansion. Strategic acquisitions such as Phibro's acquisition of Zoetis' feed additive portfolio in April 2024 strengthen portfolio breadth. Continuous innovation and sustainability initiatives remain central to competitive strategies.

Report Coverage

The veterinary therapeutics market report provides a comprehensive analysis of the global industry with a detailed evaluation of market size and value for 2025, 2026, and 2034, along with the forecast growth trajectory at a CAGR of 6.40% during 2026-2034. The report examines key product categories including veterinary drugs, veterinary vaccines, and medicated feed additives, and evaluates their adoption across companion animals and livestock. It further analyzes the market by route of administration (oral, parenteral, topical, and aerosol) and distribution channels such as veterinary clinics, veterinary hospitals, pharmacies & drug stores, and others.

The study includes an in-depth assessment of market drivers, restraints, opportunities, challenges, and emerging trends, highlighting the impact of rising pet ownership, livestock disease burden, antimicrobial resistance, and the emergence of gene and cell therapies. Regional analysis covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with country-level insights for major markets including the U.S., U.K., Germany, France, China, India, and Japan, using verified market value data for 2025 and 2026. The report also profiles leading companies such as Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim, Ceva, Virbac, and Vetoquinol, and tracks recent product approvals, acquisitions, collaborations, and logistics expansions that influence competitive positioning. Additionally, the report evaluates the impact of COVID-19, regulatory trends, pharmacovigilance systems, and sustainability initiatives shaping long-term industry development.

Conclusion

The global veterinary therapeutics market is expanding steadily from USD 47.25 billion in 2025 to USD 49.65 billion in 2026, and is projected to reach USD 81.59 billion by 2034, supported by rising pet ownership, increasing livestock production, and heightened focus on zoonotic disease control and food safety. North America dominated with 40.02% market share in 2025, driven by high pet healthcare spending, strong veterinary infrastructure, and advanced farming technologies, while Asia Pacific and Latin America are gaining momentum due to expanding livestock sectors and improving veterinary access.

Product-wise, veterinary drugs dominate with 64.87% share in 2026, reflecting high treatment demand for infectious, parasitic, and chronic animal diseases, while vaccines remain critical for outbreak prevention and feed additives support productivity in commercial farming. Companion animals accounted for 46.1% share in 2025, but livestock leads in 2026 due to rising global protein consumption and stricter biosecurity practices. Although challenges such as antimicrobial resistance, product recalls, and regulatory tightening continue to affect adoption patterns, strong R&D pipelines, growing approvals for targeted biologics, and the emergence of gene and cell therapies are reshaping future treatment paradigms. Overall, sustained innovation, preventive healthcare adoption, and expanding veterinary infrastructure are expected to keep veterinary therapeutics a vital and growing segment of global animal health.

Segmentation By Product

  • Veterinary Drugs
    • Anti-infectives
    • Anti-inflammatory
    • Parasiticides
    • Others
  • Veterinary Vaccines
    • Inactivated
    • Live Attenuated
    • Recombinant
    • Others
  • Medicated Feed Additives
    • Antimicrobials
    • Anticoccidials
    • Antiparasitics
    • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Aerosol

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region

  • North America (By Product, By Animal Type, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, By Animal Type, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, By Animal Type, By Route of Administration, By Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Animal Diseases by Key Countries, By Key Countries/ Region, 2025
  • 4.2. Pipeline Analysis
  • 4.3. Regulatory Scenario By Key Countries/ Region, 2025
  • 4.4. Pricing Analysis
  • 4.5. Pet Ownership Statistics, By Key Countries/ Region, 2025
  • 4.6. Snapshot on the Novel & Upcoming Therapies
  • 4.7. Overview of Treatment Plans for Different Animal Diseases
  • 4.8. New Product Launches, By Key Players
  • 4.9. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.10. Impact of COVID-19 on the Global Veterinary Therapeutics Market

5. Global Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Veterinary Drugs
      • 5.1.1.1. Anti-infectives
      • 5.1.1.2. Anti-inflammatory
      • 5.1.1.3. Parasiticides
      • 5.1.1.4. Others
    • 5.1.2. Veterinary Vaccines
      • 5.1.2.1. Inactivated
      • 5.1.2.2. Live Attenuated
      • 5.1.2.3. Recombinant
      • 5.1.2.4. Others
    • 5.1.3. Medicated Feed Additives
      • 5.1.3.1. Antimicrobials
      • 5.1.3.2. Anti-coccidials
      • 5.1.3.3. Antiparasitics
      • 5.1.3.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Animal Type
    • 5.2.1. Companion
      • 5.2.1.1. Feline
      • 5.2.1.2. Canine
      • 5.2.1.3. Avian
      • 5.2.1.4. Others
    • 5.2.2. Livestock
      • 5.2.2.1. Poultry
      • 5.2.2.2. Porcine
      • 5.2.2.3. Bovine
      • 5.2.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
    • 5.3.4. Aerosol
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Veterinary Hospitals
    • 5.4.2. Veterinary Clinics
    • 5.4.3. Pharmacies & Drug Stores
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Veterinary Drugs
      • 6.1.1.1. Anti-infectives
      • 6.1.1.2. Anti-inflammatory
      • 6.1.1.3. Parasiticides
      • 6.1.1.4. Others
    • 6.1.2. Veterinary Vaccines
      • 6.1.2.1. Inactivated
      • 6.1.2.2. Live Attenuated
      • 6.1.2.3. Recombinant
      • 6.1.2.4. Others
    • 6.1.3. Medicated Feed Additives
      • 6.1.3.1. Antimicrobials
      • 6.1.3.2. Anti-coccidials
      • 6.1.3.3. Antiparasitics
      • 6.1.3.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Animal Type
    • 6.2.1. Companion
      • 6.2.1.1. Feline
      • 6.2.1.2. Canine
      • 6.2.1.3. Avian
      • 6.2.1.4. Others
    • 6.2.2. Livestock
      • 6.2.2.1. Poultry
      • 6.2.2.2. Porcine
      • 6.2.2.3. Bovine
      • 6.2.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
    • 6.3.4. Aerosol
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Veterinary Hospitals
    • 6.4.2. Veterinary Clinics
    • 6.4.3. Pharmacies & Drug Stores
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Veterinary Drugs
      • 7.1.1.1. Anti-infectives
      • 7.1.1.2. Anti-inflammatory
      • 7.1.1.3. Parasiticides
      • 7.1.1.4. Others
    • 7.1.2. Veterinary Vaccines
      • 7.1.2.1. Inactivated
      • 7.1.2.2. Live Attenuated
      • 7.1.2.3. Recombinant
      • 7.1.2.4. Others
    • 7.1.3. Medicated Feed Additives
      • 7.1.3.1. Antimicrobials
      • 7.1.3.2. Anti-coccidials
      • 7.1.3.3. Antiparasitics
      • 7.1.3.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Animal Type
    • 7.2.1. Companion
      • 7.2.1.1. Feline
      • 7.2.1.2. Canine
      • 7.2.1.3. Avian
      • 7.2.1.4. Others
    • 7.2.2. Livestock
      • 7.2.2.1. Poultry
      • 7.2.2.2. Porcine
      • 7.2.2.3. Bovine
      • 7.2.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
    • 7.3.4. Aerosol
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Veterinary Hospitals
    • 7.4.2. Veterinary Clinics
    • 7.4.3. Pharmacies & Drug Stores
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Veterinary Drugs
      • 8.1.1.1. Anti-infectives
      • 8.1.1.2. Anti-inflammatory
      • 8.1.1.3. Parasiticides
      • 8.1.1.4. Others
    • 8.1.2. Veterinary Vaccines
      • 8.1.2.1. Inactivated
      • 8.1.2.2. Live Attenuated
      • 8.1.2.3. Recombinant
      • 8.1.2.4. Others
    • 8.1.3. Medicated Feed Additives
      • 8.1.3.1. Antimicrobials
      • 8.1.3.2. Anti-coccidials
      • 8.1.3.3. Antiparasitics
      • 8.1.3.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Animal Type
    • 8.2.1. Companion
      • 8.2.1.1. Feline
      • 8.2.1.2. Canine
      • 8.2.1.3. Avian
      • 8.2.1.4. Others
    • 8.2.2. Livestock
      • 8.2.2.1. Poultry
      • 8.2.2.2. Porcine
      • 8.2.2.3. Bovine
      • 8.2.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
    • 8.3.4. Aerosol
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Veterinary Hospitals
    • 8.4.2. Veterinary Clinics
    • 8.4.3. Pharmacies & Drug Stores
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Veterinary Drugs
      • 9.1.1.1. Anti-infectives
      • 9.1.1.2. Anti-inflammatory
      • 9.1.1.3. Parasiticides
      • 9.1.1.4. Others
    • 9.1.2. Veterinary Vaccines
      • 9.1.2.1. Inactivated
      • 9.1.2.2. Live Attenuated
      • 9.1.2.3. Recombinant
      • 9.1.2.4. Others
    • 9.1.3. Medicated Feed Additives
      • 9.1.3.1. Antimicrobials
      • 9.1.3.2. Anti-coccidials
      • 9.1.3.3. Antiparasitics
      • 9.1.3.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Animal Type
    • 9.2.1. Companion
      • 9.2.1.1. Feline
      • 9.2.1.2. Canine
      • 9.2.1.3. Avian
      • 9.2.1.4. Others
    • 9.2.2. Livestock
      • 9.2.2.1. Poultry
      • 9.2.2.2. Porcine
      • 9.2.2.3. Bovine
      • 9.2.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
    • 9.3.4. Aerosol
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Veterinary Hospitals
    • 9.4.2. Veterinary Clinics
    • 9.4.3. Pharmacies & Drug Stores
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Veterinary Drugs
      • 10.1.1.1. Anti-infectives
      • 10.1.1.2. Anti-inflammatory
      • 10.1.1.3. Parasiticides
      • 10.1.1.4. Others
    • 10.1.2. Veterinary Vaccines
      • 10.1.2.1. Inactivated
      • 10.1.2.2. Live Attenuated
      • 10.1.2.3. Recombinant
      • 10.1.2.4. Others
    • 10.1.3. Medicated Feed Additives
      • 10.1.3.1. Antimicrobials
      • 10.1.3.2. Anti-coccidials
      • 10.1.3.3. Antiparasitics
      • 10.1.3.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Animal Type
    • 10.2.1. Companion
      • 10.2.1.1. Feline
      • 10.2.1.2. Canine
      • 10.2.1.3. Avian
      • 10.2.1.4. Others
    • 10.2.2. Livestock
      • 10.2.2.1. Poultry
      • 10.2.2.2. Porcine
      • 10.2.2.3. Bovine
      • 10.2.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
    • 10.3.4. Aerosol
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Veterinary Hospitals
    • 10.4.2. Veterinary Clinics
    • 10.4.3. Pharmacies & Drug Stores
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Zoetis Services LLC
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck Animal Health
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Elanco
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Boehringer Ingelheim International GmbH.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ceva
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Vetoquinol
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Virbac
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Phibro Animal Health Corporation
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Panav Bio Tech.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 3: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 4: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 5: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 6: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 7: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 8: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 9: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 11: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 12: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 13: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 14: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 15: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 16: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 17: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 18: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 19: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 21: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 22: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 23: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 24: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 25: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 26: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 27: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 28: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 29: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 32: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 33: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 34: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 35: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 36: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 37: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 38: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 39: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 40: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 41: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 42: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 43: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 44: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 45: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 46: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 47: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 48: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 49: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 50: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 51: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 52: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 53: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 54: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 55: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 56: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 57: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 58: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 59: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 60: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Veterinary Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Veterinary Therapeutics Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025 & 2034
  • Figure 4: Global Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Veterinary Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 8: North America Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 9: North America Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 10: North America Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 11: North America Veterinary Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Veterinary Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Veterinary Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 18: Europe Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 19: Europe Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 20: Europe Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 21: Europe Veterinary Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Veterinary Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Veterinary Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 28: Asia Pacific Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 29: Asia Pacific Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 30: Asia Pacific Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 31: Asia Pacific Veterinary Therapeutics Market Value (USD billion),by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Veterinary Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Veterinary Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 38: Latin America Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 39: Latin America Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 40: Latin America Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 41: Latin America Veterinary Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Veterinary Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Veterinary Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 48: Middle East & Africa Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 49: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 50: Middle East & Africa Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 51: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Veterinary Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 57: Global Veterinary Therapeutics Market Share (%), By Company, 2025